Spain has become the fourth European country to approve thesale Bio-Technology General Corp.'s recombinant human growthhormone to treat short stature, the New York-based companysaid Tuesday.
Spain, with $100 million in hGH sales in 1990, is the largestsingle market for hGH in Europe, according to BTGC. TotalEuropean sales are about $300 million annually. SmithKlineBeecham Pharmaceuticals will market the product under thename Eskatrope. The drug has received approvals in theNetherlands, Denmark and Luxembourg.
BTGC stock (NASDAQ:BTGC) closed unchanged at $6.75 onTuesday.
(c) 1997 American Health Consultants. All rights reserved.